Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
Product
TLANDO®
TLANDO®
Investors/Media
Overview
Press Releases
Events
Presentations
Financials & Filings
Stock Information
Investor FAQs
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Presentations
Presentations
Oral Brexanolone for Major Depressive Disorder (MDD)
View
LPCN 2203 Oral NAS for Essential Tremor
View
Corporate Presentation
View
LPCN 1154 – Oral Brexanolone for Postpartum Depression (PPD)
View
LPCN 1154 for Depression R&D Event, July 9th 2025
View
LPCN 1154 Topline Results – PK Bridge Clinical Study
View
KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management
View
LPCN 2401 for Obesity Management
View
LPCN 1148 Management of Liver Cirrhosis
View
LPCN 1148 Phase 2 Study Topline Results
View
AASLD Poster 11/13/2023
View
AASLD Presentation 11/13/2023
View
EASL Congress Presentation
View
LPCN 2101 Treatment of Epilepsy
View
LPCN 1107 Pioneering A Solution to the Preterm Birth Health Crisis
View
LPCN 1144 Presentation
View
LPCN 1144 LiFT 12 Week Study Results
View
LPCN 1144 Presentation-LiFT Topline 36 Week Results
View
LPCN 1144 Presentation-OLE Topline Results
View
LPCN 1144 for Nonalcoholic Steatohepatitis (NASH)
View
LPCN 1111 Once Daily Oral Testosterone
View
TLANDO® (LPCN 1021) The Convenient Oral Testosterone Replacement Therapy without Titration Requirement
View
Innovating beyond
boundaries for patients